Adlai Nortye Is A Global Clinical Stage Biopharmaceutical Company Founded In 2016Focused On Developing Innovative Targeted And Immune Modulating Therapies For Cancerwith Headquarters And R&D Centers In The U Sand Chinathe Company Aims To Transform Aggressive Cancers Into Manageable Conditions And Improve Patient Survival And Quality Of Life The Company S Lead Candidatebuparlisiban2025 Is A Pan Pi3K Inhibitor Currently In A Phase 3 Trial For Recurrent Or Metastatic Head And Neck Squamous Cell Carcinomaadlai Nortye Also Has Several Other Candidates In Its Pipelineincluding An4005An Oral Pd L1 Inhibitoran8025A Trifunctional Fusion Proteinand An9025An Oral Pan Ras Oninhibitorthe Company Emphasizes Global Partnerships And Engages In Drug Discoveryclinical Developmentand Commercializationfocusing On Combination Therapies And Biomarker Driven Approaches
